We have excluded third-party attorney’s fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcom’s patent infringement litigation against Abbott Diabetes Care, Inc., as ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM), the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (Nasdaq: DXCM) today reported preliminary, unaudited results for the fourth quarter ended December 31, 2024 with total revenue of at least $1.113 billion, an ...
At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 showing an overall mean absolute relative difference (MARD) of 8.0%, making it ...
The accompanying press release dated July 30, 2025 contains non-GAAP financial measures. These non-GAAP financial measures include organic revenue, non-GAAP gross profit margin, non-GAAP operating ...
DexCom reports quarterly earnings of 43 cents per share which beat the analyst consensus estimate of 39 cents by 10.26%. Quarterly sales come in at $1.004 billion which missed the analyst consensus ...
Reports Q3 revenue $994.2M, consensus $990.71M. “Dexcom’s (DXCM) third quarter results were in line with our expectations as our team responded quickly to the business dynamics that emerged earlier ...
SAN DIEGO (AP) _ DexCom Inc. (DXCM) on Wednesday reported a loss of $2 million in its third quarter. On a per-share basis, the San Diego-based company said it had a loss of 2 cents. Losses, adjusted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback